India’s IPCA Gets U.S. Clearance For Migraine Generic
This article was originally published in PharmAsia News
The U.S. FDA has cleared a generic blood-pressure drug made by Indian Pharmaceuticals Combine Association. Marketing approval allows IPCA to produce its generic of Wyeth's Inderide (propranolol hydrochloride) tablets for treating migraine headaches, a $24.1 million-a-year product. IPCA already makes and markets its drugs in 100 countries, with exports accounting for half of its business. (Click here for more
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.